Condition: Stroke Patients · Sponsor: Assistance Publique - Hôpitaux de Paris
Introduction: Stroke affects one person every 4 minutes in France (i.e. more than 140,000 new cases per year) resulting in cognitive and motor disorders. Aphasia is one of the most devastating cognitive disorders that persist in the late phase. However, early treatment of aphasia can improve the effects of rehabilitation. Identifying, as early as possible, the patients most at risk of presenting persistent language disorders in the late phase would make it possible to improve their management and increase the effects of cognitive rehabilitation on their language abilities. The aim of this project is to evaluate whether the Core Assessment of Language Processing (CALAP) assessed in the acute phase of stroke can predict language abilities in the late phase. Hypothesis/Objective: The primary objective is to determine whether the language abilities of patients in the acute phase of stroke can be used to predict language abilities in the late phase. Secondary objectives are to determine whether prediction can be improved with (1) brain MRI data and (2) neuropsychological assessment data. The (3) secondary objective is to determine whether cognitive abilities at the chronic phase can be predicted by language performance in the acute phase. The (4) secondary objective is to assess whether language rehabilitation modifies the predictive power of the language abilities assessed with the CALAP. Method: Patients will be included during their hospitalization after a brain vascular…
This description comes directly from the study's public registry record.
Anne-Catherine BACHOUD-LEVI, MD, PhD · 01 49 81 43 01 · anne-catherine.bachoud-levi@aphp.fr
Tiffany MONNIER, MD, PhD · 01 45 17 84 86 · tiffany.monnier@aphp.fr
Always discuss trial participation with your own doctor first.
| Assistance Publique Hôpitaux de Paris - Hôpital Henri Mondor | Créteil, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06817642